

REFERENCES

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984;1(8390):1311-5.
2. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002;347(15):1175-86.
3. Hopkins RJ, Morris JG, Jr. *Helicobacter pylori*: the missing link in perspective. *Am J Med* 1994;97(3):265-77.
4. Thomas JE, Dale A, Harding M, Coward WA, Cole TJ, Weaver LT. *Helicobacter pylori* colonization in early life. *Pediatr Res* 1999;45(2):218-23.
5. Deltenre M, de Koster E. How come I've got it? (A review of *Helicobacter pylori* transmission). *Eur J Gastroenterol Hepatol* 2000;12(5):479-82.
6. Hassall E. Peptic ulcer disease and current approaches to *Helicobacter pylori*. *J Pediatr* 2001;138(4):462-8.
7. Lindkvist P, Enquesselassie F, Asrat D, Nilsson I, Muhe L, Giesecke J. *Helicobacter pylori* infection in Ethiopian children: a cohort study. *Scand J Infect Dis* 1999;31(5):475-80.
8. Malaty HM, Logan ND, Graham DY, Ramchatesingh JE. *Helicobacter pylori* infection in preschool and school-aged minority children: effect of socioeconomic indicators and breast-feeding practices. *Clin Infect Dis* 2001;32(10):1387-92.
9. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991;325(16):1132-6.

10. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Jr., Saeed ZA, et al. Effect of treatment of *Helicobacter pylori* infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. *Ann Intern Med* 1992;116(9):705-8.
11. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991;325(16):1127-31.
12. Blaser MJ. Ecology of *Helicobacter pylori* in the human stomach. *J Clin Invest* 1997;100(4):759-62.
13. Dixon MF. *Helicobacter pylori* and peptic ulceration: histopathological aspects. *J Gastroenterol Hepatol* 1991;6(2):125-30.
14. Tytgat GN, Noach LA, Rauws EA. *Helicobacter pylori* infection and duodenal ulcer disease. *Gastroenterol Clin North Am* 1993;22(1):127-39.
15. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of *Helicobacter pylori*. *Lancet* 1993;342(8871):575-7.
16. Shimoyama T, Crabtree JE. Bacterial factors and immune pathogenesis in *Helicobacter pylori* infection. *Gut* 1998;43 Suppl 1:S2-5.
17. Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of *Helicobacter pylori* genes responsible for urease activity. *J Bacteriol* 1991;173(6):1920-31.
18. Leying H, Suerbaum S, Geis G, Haas R. Cloning and genetic characterization of a *Helicobacter pylori* flagellin gene. *Mol Microbiol* 1992;6(19):2863-74.

19. Suerbaum S, Josenhans C, Labigne A. Cloning and genetic characterization of the *Helicobacter pylori* and *Helicobacter mustelae* flaB flagellin genes and construction of *H. pylori* flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. *J Bacteriol* 1993;175(11):3278-88.
20. Spiegelhalder C, Gerstenecker B, Kersten A, Schiltz E, Kist M. Purification of *Helicobacter pylori* superoxide dismutase and cloning and sequencing of the gene. *Infect Immun* 1993;61(12):5315-25.
21. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* 1993;262(5141):1892-5.
22. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, et al. Molecular characterization of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci U S A* 1993;90(12):5791-5.
23. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR. Variants of the 3' region of the cagA gene in *Helicobacter pylori* isolates from patients with different *H. pylori*-associated diseases. *J Clin Microbiol* 1998;36(8):2258-63.
24. Asahi M, Azuma T, Ito S, Ito Y, Suto H, Nagai Y, et al. *Helicobacter pylori* CagA protein can be tyrosine phosphorylated in gastric epithelial cells. *J Exp Med* 2000;191(4):593-602.
25. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci U S A* 1996;93(25):14648-53.

26. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, et al. Major virulence factors, VacA and CagA, are commonly positive in *Helicobacter pylori* isolates in Japan. *Gut* 1998;42(3):338-43.
27. Weel JF, van der Hulst RW, Gerrits Y, Roorda P, Feller M, Dankert J, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and *Helicobacter pylori*-related diseases. *J Infect Dis* 1996;173(5):1171-5.
28. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection. *Gut* 1997;40(3):297-301.
29. Bulent K, Murat A, Esin A, Fatih K, H MM, Hakan H, et al. Association of CagA and VacA presence with ulcer and non-ulcer dyspepsia in a Turkish population. *World J Gastroenterol* 2003;9(7):1580-3.
30. Graham DY, Yamaoka Y. H. *pylori* and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. *Helicobacter* 1998;3(3):145-51.
31. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive *Helicobacter pylori* strains. *Gut* 1997;41(4):442-51.
32. Yamaoka Y, Kita M, Kodama T, Sawai N, Tanahashi T, Kashima K, et al. Chemokines in the gastric mucosa in *Helicobacter pylori* infection. *Gut* 1998;42(5):609-17.
33. Zhang Y, Liu H, Zhou K. Lack of correlation of vacA genotype, cagA gene of *Helicobacter pylori* and their expression products with various gastroduodenal diseases. *Chin Med J (Engl)* 2001;114(7):703-6.

34. Kim SY, Woo CW, Lee YM, Son BR, Kim JW, Chae HB, et al. Genotyping CagA, VacA subtype, IceA1, and BabA of *Helicobacter pylori* isolates from Korean patients, and their association with gastroduodenal diseases. *J Korean Med Sci* 2001;16(5):579-84.
35. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between *Helicobacter pylori* iceA, cagA, and vacA status and clinical outcome: studies in four different countries. *J Clin Microbiol* 1999;37(7):2274-9.
36. Wong BC, Yin Y, Berg DE, Xia HH, Zhang JZ, Wang WH, et al. Distribution of distinct vacA, cagA and iceA alleles in *Helicobacter pylori* in Hong Kong. *Helicobacter* 2001;6(4):317-24.
37. Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J Med Microbiol* 1988;26(2):93-9.
38. Atherton JC, Cao P, Peek RM, Jr., Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem* 1995;270(30):17771-7.
39. Rudi J, Kolb C, Maiwald M, Kuck D, Sieg A, Galle PR, et al. Diversity of *Helicobacter pylori* vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. *J Clin Microbiol* 1998;36(4):944-8.
40. Phadnis SH, Ilver D, Janzon L, Normark S, Westblom TU. Pathological significance and molecular characterization of the vacuolating toxin gene of *Helicobacter pylori*. *Infect Immun* 1994;62(5):1557-65.
41. Cover TL. The vacuolating cytotoxin of *Helicobacter pylori*. *Mol Microbiol* 1996;20(2):241-6.

42. Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J Biol Chem* 1994;269(14):10566-73.
43. Atherton JC, Peek RM, Jr., Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* 1997;112(1):92-9.
44. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W, et al. Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*. *Gastroenterology* 1998;115(1):58-66.
45. Peek RM, Jr., Thompson SA, Donahue JP, Tham KT, Atherton JC, Blaser MJ, et al. Adherence to gastric epithelial cells induces expression of a *Helicobacter pylori* gene, *iceA*, that is associated with clinical outcome. *Proc Assoc Am Physicians* 1998;110(6):531-44.
46. Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of *iceA* genotypes in South African *Helicobacter pylori* strains and relationship to clinically significant disease. *Gut* 2001;49(5):629-35.
47. Skirrow MB. Taxonomy and biotyping: Report on the session. In: Rowe B, editor. *Campylobacter* II. London: Public Health Laboratory Service; 1983. p. 33-38.
48. Marshall BJ, Royce H, Annear DJ. Original isolation of *Campylobacter pyloridis* from the human gastric mucosa. *Microbiol Lett* 1984;25:83-88.
49. Marshall BJ, Goodwin CS. Revised nomenclature of *C. pyloridis*. *Int J Syst Bacteriol* 1987;37:68.

50. Goodwin CS, McCulloch RK, Armstrong JA, Wee SH. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (*Campylobacter pyloridis*) from the human gastric mucosa. *J Med Microbiol* 1985;19(2):257-67.
51. Archer JR, Romero S, Ritchie AE, Hamacher ME, Steiner BM, Bryner JH, et al. Characterization of an unclassified microaerophilic bacterium associated with gastroenteritis. *J Clin Microbiol* 1988;26(1):101-5.
52. Costa K, Bacher G, Allmaier G, Dominguez-Bello MG, Engstrand L, Falk P, et al. The morphological transition of *Helicobacter pylori* cells from spiral to coccoid is preceded by a substantial modification of the cell wall. *J Bacteriol* 1999;181(12):3710-5.
53. Catrenich CE, Makin KM. Characterization of the morphologic conversion of *Helicobacter pylori* from bacillary to coccoid forms. *Scand J Gastroenterol Suppl* 1991;181:58-64.
54. Cellini L, Allocati N, Di Campli E, Dainelli B. *Helicobacter pylori*: a fickle germ. *Microbiol Immunol* 1994;38(1):25-30.
55. Hazell SL, Lee A, Brady L, Hennessy W. *Campylobacter pyloridis* and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. *J Infect Dis* 1986;153(4):658-63.
56. Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonisation of gnotobiotic piglets by *Helicobacter pylori*. *J Med Microbiol* 1992;37(2):123-7.

57. Geis G, Suerbaum S, Forsthoff B, Leyer H, Opferkuch W. Ultrastructure and biochemical studies of the flagellar sheath of *Helicobacter pylori*. *J Med Microbiol* 1993;38(5):371-7.
58. Lee A, Phillips MW, O'Rourke JL, Paster BJ, Dewhirst FE, Fraser GJ, et al. *Helicobacter muridarum* sp. nov., a microaerophilic helical bacterium with a novel ultrastructure isolated from the intestinal mucosa of rodents. *Int J Syst Bacteriol* 1992;42(1):27-36.
59. Paster BJ, Lee A, Fox JG, Dewhirst FE, Tordoff LA, Fraser GJ, et al. Phylogeny of *Helicobacter felis* sp. nov., *Helicobacter mustelae*, and related bacteria. *Int J Syst Bacteriol* 1991;41(1):31-8.
60. Shen Z, Fox JG, Dewhirst FE, Paster BJ, Foltz CJ, Yan L, et al. *Helicobacter rodentium* sp. nov., a urease-negative *Helicobacter* species isolated from laboratory mice. *Int J Syst Bacteriol* 1997;47(3):627-34.
61. Bode G, Mauch F, Ditschuneit H, Malfertheiner P. Identification of structures containing polyphosphate in *Helicobacter pylori*. *J Gen Microbiol* 1993;139(12):3029-33.
62. Marshall BJ, Helen M, O'Rourke JL. Bacteriology and taxonomy of *Helicobacter pylori*: Gastroenterology Clinic of North America, 2000.
63. Chalk PA, Roberts AD, Blows WM. Metabolism of pyruvate and glucose by intact cells of *Helicobacter pylori* studied by ¹³C NMR spectroscopy. *Microbiology* 1994;140 (Pt 8):2085-92.
64. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, et al. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature* 1997;388(6642):539-47.

65. Mobley HL, Mendz GL, Hazell SL. *Helicobacter pylori*. Washington, DC: ASM Press American Society for Microbiology, 2001.
66. Andersen LP, Kiilerick S, Pedersen G, Thoreson AC, Jorgensen F, Rath J, et al. An analysis of seven different methods to diagnose *Helicobacter pylori* infections. *Scand J Gastroenterol* 1998;33(1):24-30.
67. Andersen LP, Espersen F. Immunoglobulin G antibodies to *Helicobacter pylori* in patients with dyspeptic symptoms investigated by the western immunoblot technique. *J Clin Microbiol* 1992;30(7):1743-51.
68. Andersen LP, Norgaard A, Holck S, Blom J, Elsborg L. Isolation of a "*Helicobacter heilmanii*"-like organism from the human stomach. *Eur J Clin Microbiol Infect Dis* 1996;15(1):95-6.
69. Andersen LP, Raskov H, Elsborg L, Holck S, Justesen T, Fischer Hansen B, et al. Prevalence of antibodies against heat-stable antigens from *Helicobacter pylori* in patients with dyspeptic symptoms and normal persons. *Apmis* 1992;100(9):779-89.
70. Nichols L, Sughayer M, DeGirolami PC, Balogh K, Pleskow D, Eichelberger K, et al. Evaluation of diagnostic methods for *Helicobacter pylori* gastritis. *Am J Clin Pathol* 1991;95(6):769-73.
71. Goodwin CS, Blincow ED, Warren JR, Waters TE, Sanderson CR, Easton L. Evaluation of cultural techniques for isolating *Campylobacter pyloridis* from endoscopic biopsies of gastric mucosa. *J Clin Pathol* 1985;38(10):1127-31.
72. Goodwin CS, Worsley BW. Microbiology of *Helicobacter pylori*. *Gastroenterol Clin North Am* 1993;22(1):5-19.

73. Krajden S, Bohnen J, Anderson J, Kempston J, Fuksa M, Matlow A, et al. Comparison of selective and nonselective media for recovery of *Campylobacter pylori* from antral biopsies. *J Clin Microbiol* 1987;25(6):1117-8.
74. Olivieri R, Bugnoli M, Armellini D, Bianciardi S, Rappuoli R, Bayeli PF, et al. Growth of *Helicobacter pylori* in media containing cyclodextrins. *J Clin Microbiol* 1993;31(1):160-2.
75. Hazell SL, Markesich DC, Evans DJ, Evans DG, Graham DY. Influence of media supplements on growth and survival of *Campylobacter pylori*. *Eur J Clin Microbiol Infect Dis* 1989;8(7):597-602.
76. Jones DM, Lessells AM, Eldridge J. *Campylobacter* like organisms on the gastric mucosa: culture, histological, and serological studies. *J Clin Pathol* 1984;37(9):1002-6.
77. Kasper G, Dickgiesser N. Isolation from gastric epithelium of *Campylobacter*-like bacteria that are distinct from "*Campylobacter pyloridis*". *Lancet* 1985;1(8420):111-2.
78. Hessey SJ, Spencer J, Wyatt JI, Sobala G, Rathbone BJ, Axon AT, et al. Bacterial adhesion and disease activity in *Helicobacter* associated chronic gastritis. *Gut* 1990;31(2):134-8.
79. Westblom TU, Madan E, Midkiff BR, Adkins VW, Subik MA. Failure of *Campylobacter pylori* to grow in commercial blood culture systems. *J Clin Microbiol* 1988;26(5):1029-30.
80. Westblom TU, Madan E, Midkiff BR. Egg yolk emulsion agar, a new medium for the cultivation of *Helicobacter pylori*. *J Clin Microbiol* 1991;29(4):819-21.

81. Roosendaal R, Kuipers EJ, Pena AS, de Graaff J. Recovery of *Helicobacter pylori* from gastric biopsy specimens is not dependent on the transport medium used. *J Clin Microbiol* 1995;33(10):2798-800.
82. Soltesz V, Zeeberg B, Wadstrom T. Optimal survival of *Helicobacter pylori* under various transport conditions. *J Clin Microbiol* 1992;30(6):1453-6.
83. Andersen LP, Holck S, Povlsen CO, Elsborg L, Justesen T. *Campylobacter pyloridis* in peptic ulcer disease. I. Gastric and duodenal infection caused by *C. pyloridis*: histopathologic and microbiologic findings. *Scand J Gastroenterol* 1987;22(2):219-24.
84. Andersen LP, Elsborg L, Justesen T. *Campylobacter pylori* in peptic ulcer disease. II. Endoscopic findings and cultivation of *C. pylori*. *Scand J Gastroenterol* 1988;23(6):760-4.
85. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996;20(10):1161-81.
86. Berry V, Jennings K, Woodnutt G. Bactericidal and morphological effects of amoxicillin on *Helicobacter pylori*. *Antimicrob Agents Chemother* 1995;39(8):1859-61.
87. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of *Helicobacter pylori* from feces of patients with dyspepsia in the United Kingdom. *Gastroenterology* 1994;107(6):1671-4.
88. Talley NJ, Cameron AJ, Shorter RG, Zinsmeister AR, Phillips SF. *Campylobacter pylori* and Barrett's esophagus. *Mayo Clin Proc* 1988;63(12):1176-80.

89. Thomas JE, Gibson GR, Darboe MK, Dale A, Weaver LT. Isolation of *Helicobacter pylori* from human faeces. *Lancet* 1992;340(8829):1194-5.
90. Gubbins GP, Moritz TE, Marsano LS, Talwalkar R, McClain CJ, Mendenhall CL. *Helicobacter pylori* is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis: the ammonia hypothesis revisited. The Veterans Administration Cooperative Study Group No. 275. *Am J Gastroenterol* 1993;88(11):1906-10.
91. Murray LJ, Bamford KB, O'Reilly DP, McCrum EE, Evans AE. *Helicobacter pylori* infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. *Br Heart J* 1995;74(5):497-501.
92. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections with coronary heart disease and cardiovascular risk factors. *Bmj* 1995;311(7007):711-4.
93. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of *Helicobacter pylori* and other *Helicobacter* species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. *J Clin Microbiol* 2000;38(3):1072-6.
94. Bravos ED, Gilman RH. Accurate diagnosis of *Helicobacter pylori*. Other tests. *Gastroenterol Clin North Am* 2000;29(4):925-9, xii.
95. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of *Helicobacter pylori* or intestinal metaplasia: role of the Sydney System. *Hum Pathol* 1999;30(1):72-7.
96. Perez-Perez GI. Accurate diagnosis of *Helicobacter pylori*. Culture, including transport. *Gastroenterol Clin North Am* 2000;29(4):879-84.

97. Mobley HL, Cortesia MJ, Rosenthal LE, Jones BD. Characterization of urease from *Campylobacter pylori*. *J Clin Microbiol* 1988;26(5):831-6.
98. Midolo P, Marshall BJ. Accurate diagnosis of *Helicobacter pylori*. Urease tests. *Gastroenterol Clin North Am* 2000;29(4):871-8.
99. Vaira D, Vakil N. Blood, urine, stool, breath, money, and *Helicobacter pylori*. *Gut* 2001;48(3):287-9.
100. Chey WD, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. *Am J Gastroenterol* 1997;92(3):446-50.
101. Lerang F, Haug JB, Moum B, Mowinckel P, Berge T, Ragnhildstveit E, et al. Accuracy of IgG serology and other tests in confirming *Helicobacter pylori* eradication. *Scand J Gastroenterol* 1998;33(7):710-5.
102. Cutler AF, Prasad VM, Santogade P. Four-year trends in *Helicobacter pylori* IgG serology following successful eradication. *Am J Med* 1998;105(1):18-20.
103. Monteiro L, de Mascarel A, Sarrasqueta AM, Bergey B, Barberis C, Talby P, et al. Diagnosis of *Helicobacter pylori* infection: noninvasive methods compared to invasive methods and evaluation of two new tests. *Am J Gastroenterol* 2001;96(2):353-8.
104. Breuer T, Malaty HM, Graham DY. The epidemiology of *H. pylori* - associated gastroduodenal diseases. In: Smith PD, editor. *The immunobiology of H. pylori: From Pathogenesis to prevention*. Philadelphia: Lippincott-Raven, 1997:1-14.
105. Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, et al. Traces of human migrations in *Helicobacter pylori* populations. *Science* 2003;299(5612):1582-5.

106. Malaty HM, Evans DG, Evans DJ, Jr., Graham DY. *Helicobacter pylori* in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. *Gastroenterology* 1992;103(3):813-6.
107. Cullen DJ, Collins BJ, Christiansen KJ, Epis J, Warren JR, Surveyor I, et al. When is *Helicobacter pylori* infection acquired? *Gut* 1993;34(12):1681-2.
108. Sipponen P, Kosunen TU, Samloff IM, Heinonen OP, Siurala M. Rate of *Helicobacter pylori* acquisition among Finnish adults: a fifteen year follow-up. *Scand J Gastroenterol* 1996;31(3):229-32.
109. Malaty HM, Evans DJ, Jr., Abramovitch K, Evans DG, Graham DY. *Helicobacter pylori* infection in dental workers: a seroepidemiology study. *Am J Gastroenterol* 1992;87(12):1728-31.
110. Graham DY, Malaty HM, Evans DG, Evans DJ, Jr., Klein PD, Adam E. Epidemiology of *Helicobacter pylori* in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. *Gastroenterology* 1991;100(6):1495-501.
111. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection. *Gut* 1994;35(6):742-5.
112. Graham DY, Malaty HM, Go MF. Are there susceptible hosts to *Helicobacter pylori* infection? *Scand J Gastroenterol Suppl* 1994;205:6-10.
113. Go MF, Graham DY. Determinants of clinical outcome of *H. pylori* infection: duodenal ulcer. In: Tytgat GN, editor. *Helicobacter pylori: Basic Mechanisms to Clinical Cure*. Netherlands: Kluwer Academic Publishers, 1994: 421-428.

114. Raymond J, Thiberg JM, Chevalier C, Kalach N, Bergeret M, Labigne A, et al. Genetic and transmission analysis of *Helicobacter pylori* strains within a family. *Emerg Infect Dis* 2004;10(10):1816-21.
115. Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL. Co-twin study of the effect of environment and dietary elements on acquisition of *Helicobacter pylori* infection. *Am J Epidemiol* 1998;148(8):793-7.
116. Murray LJ, McCrum EE, Evans AE, Bamford KB. Epidemiology of *Helicobacter pylori* infection among 4742 randomly selected subjects from Northern Ireland. *Int J Epidemiol* 1997;26(4):880-7.
117. Rothenbacher D, Bode G, Winz T, Berg G, Adler G, Brenner H. *Helicobacter pylori* in out-patients of a general practitioner: prevalence and determinants of current infection. *Epidemiol Infect* 1997;119(2):151-7.
118. Goodman KJ, Correa P. Transmission of *Helicobacter pylori* among siblings. *Lancet* 2000;355(9201):358-62.
119. Perez-Perez GI, Witkin SS, Decker MD, Blaser MJ. Seroprevalence of *Helicobacter pylori* infection in couples. *J Clin Microbiol* 1991;29(3):642-4.
120. Malaty HM, Kim JG, Kim SD, Graham DY. Prevalence of *Helicobacter pylori* infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. *Am J Epidemiol* 1996;143(3):257-62.
121. Tosun SY, Kasirga E, Ertan P, Aksu S. Evidence against the fecal-oral route of transmission for *Helicobacter pylori* infection in childhood. *Med Sci Monit* 2003;9(11):CR489-92.

122. Cellini L, Allocati N, Piattelli A, Petrelli I, Fanci P, Dainelli B. Microbiological evidence of *Helicobacter pylori* from dental plaque in dyspeptic patients. *New Microbiol* 1995;18(2):187-92.
123. Czesnikiewicz-Guzik M, Karczewska E, Bielanski W, Guzik TJ, Kapera P, Targosz A, et al. Association of the presence the *Helicobacter pylori* in the oral cavity and in the stomach. *J Physiol Pharmacol* 2004;55 Suppl 2:105-15.
124. Siddiq M, Haseeb ur R, Mahmood A. Evidence of *Helicobacter pylori* infection in dental plaque and gastric mucosa. *J Coll Physicians Surg Pak* 2004;14(4):205-7.
125. Wilhoite SL, Ferguson DA, Jr., Soike DR, Kalbfleisch JH, Thomas E. Increased prevalence of *Helicobacter pylori* antibodies among nurses. *Arch Intern Med* 1993;153(6):708-12.
126. Go MF, Crowe SE. Virulence and pathogenicity of *Helicobacter pylori*. *Gastroenterol Clin North Am* 2000;29(3):649-70.
127. Vorobjova T, Maaros HI, Sipponen P, Villako K, Uibo R. Apoptosis in different compartments of antrum and corpus mucosa in chronic *Helicobacter pylori* gastritis. An 18-year follow-up study. *Scand J Gastroenterol* 2001;36(2):136-43.
128. Andersson SI, Hovellius B, Molstad S, Wadstrom T. Dyspepsia in general practice: psychological findings in relation to *Helicobacter pylori* serum antibodies. *J Psychosom Res* 1994;38(3):241-7.
129. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating *Helicobacter pylori* infection in patients with nonulcer dyspepsia. *N Engl J Med* 1998;339(26):1869-74.

130. Jaakkimainen RL, Boyle E, Tudiver F. Is *Helicobacter pylori* associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. *Bmj* 1999;319(7216):1040-4.
131. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of *Helicobacter pylori* infection--the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002;16(2):167-80.
132. Graham DY, Yamaoka Y. Disease-specific *Helicobacter pylori* virulence factors: the unfulfilled promise. *Helicobacter* 2000;5 Suppl 1:S3-9; discussion S27-31.
133. Cohen H. Peptic ulcer and *Helicobacter pylori*. *Gastroenterol Clin North Am* 2000;29(4):775-89.
134. Huang JQ, Sridhar S, Hunt RH. Role of *Helicobacter pylori* infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet* 2002;359(9300):14-22.
135. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of *Helicobacter pylori* and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. *Lancet* 2002;359(9300):9-13.
136. Blaser MJ. Hypothesis: the changing relationships of *Helicobacter pylori* and humans: implications for health and disease. *J Infect Dis* 1999;179(6):1523-30.
137. Vakil NB. Review article: gastro-oesophageal reflux disease and *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2002;16 Suppl 1:47-51.
138. Master SS. Gastric carcinoma. *Dis Mon* 2004;50(10):532-9.

139. Thong-Ngam D, Tangkijvanich P, Mahachai V, Kullavanijaya P. Current status of gastric cancer in Thai patients. *J Med Assoc Thai* 2001;84(4):475-82.
140. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992;52(24):6735-40.
141. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000;404(6776):398-402.
142. Furuta T, Shirai N, Takashima M, Xiao F, Sugimura H. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with *Helicobacter pylori*. *Am J Med* 2002;112(2):141-3.
143. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. *Gastroenterology* 2002;123(1):92-105.
144. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, et al. *Helicobacter pylori* and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst* 2002;94(22):1680-7.
145. Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. *Helicobacter pylori* impairs DNA mismatch repair in gastric epithelial cells. *Gastroenterology* 2002;123(2):542-53.
146. Yu J, Leung WK, Go MY, Chan MC, To KF, Ng EK, et al. Relationship between *Helicobacter pylori* babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. *Gut* 2002;51(4):480-4.

147. Maeda S, Yoshida H, Mitsuno Y, Hirata Y, Ogura K, Shiratori Y, et al. Analysis of apoptotic and antiapoptotic signalling pathways induced by *Helicobacter pylori*. *Gut* 2002;50(6):771-8.
148. Schuster M. [*Helicobacter pylori*: reasons for eradication]. *Schweiz Rundsch Med Prax* 2004;93(51-52):2135-41.
149. Yang HB, Sheu BS, Wang JT, Lin ST, Wu JJ. Serological responses of FldA and small-molecular-weight proteins of *Helicobacter pylori*: correlation with the presence of the gastric MALT tissue. *Helicobacter* 2004;9(1):81-6.
150. Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Muller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication of *Helicobacter pylori*. *Lancet* 2002;360(9332):547-8.
151. Mueller A, O'Rourke J, Grimm J, Guillemin K, Dixon MF, Lee A, et al. Distinct gene expression profiles characterize the histopathological stages of disease in *Helicobacter*-induced mucosa-associated lymphoid tissue lymphoma. *Proc Natl Acad Sci U S A* 2003;100(3):1292-7.
152. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. *Helicobacter pylori* virulence and genetic geography. *Science* 1999;284(5418):1328-33.
153. Suzuki J, Muraoka H, Ohnishi H. Evidence of the colonization of urease negative variants of *Helicobacter pylori* in Mongolian gerbils. *Gastroenterology* 1999;116:A324.
154. Chattopadhyay S, Datta S, Chowdhury A, Chowdhury S, Mukhopadhyay AK, Rajendran K, et al. Virulence genes in *Helicobacter pylori* strains from West Bengal residents

- with overt *H. pylori*-associated disease and healthy volunteers. *J Clin Microbiol* 2002;40(7):2622-5.
155. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS, et al. Mucosal IgA recognition of *Helicobacter pylori* 120 kDa protein, peptic ulceration, and gastric pathology. *Lancet* 1991;338(8763):332-5.
156. Crabtree JE, Farmery SM, Lindley IJ, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strains of *Helicobacter pylori* and interleukin-8 in gastric epithelial cell lines. *J Clin Pathol* 1994;47(10):945-50.
157. Day AS, Su B, Ceponis PJ, Jones NL, Yau E, Sieveking D, et al. *Helicobacter pylori* infection induces interleukin-18 production in gastric epithelial (AGS) cells. *Dig Dis Sci* 2004;49(11-12):1830-5.
158. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, et al. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 2002;295(5555):683-6.
159. Selbach M, Moese S, Hurwitz R, Hauck CR, Meyer TF, Backert S. The *Helicobacter pylori* CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. *Embo J* 2003;22(3):515-28.
160. Tsutsumi R, Higashi H, Higuchi M, Okada M, Hatakeyama M. Attenuation of *Helicobacter pylori* CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. *J Biol Chem* 2003;278(6):3664-70.
161. Mimuro H, Suzuki T, Tanaka J, Asahi M, Haas R, Sasakawa C. Grb2 is a key mediator of *Helicobacter pylori* CagA protein activities. *Mol Cell* 2002;10(4):745-55.

162. Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of *Helicobacter pylori*. *Nat Genet* 2003;33(3):375-81.
163. Schraw W, Li Y, McClain MS, van der Goot FG, Cover TL. Association of *Helicobacter pylori* vacuolating toxin (VacA) with lipid rafts. *J Biol Chem* 2002;277(37):34642-50.
164. Smoot DT, Resau JH, Earlington MH, Simpson M, Cover TL. Effects of *Helicobacter pylori* vacuolating cytotoxin on primary cultures of human gastric epithelial cells. *Gut* 1996;39(96):795-9.
165. Molinari M, Galli C, Norais N, Telford JL, Rappuoli R, Luzio JP, et al. Vacuoles induced by *Helicobacter pylori* toxin contain both late endosomal and lysosomal markers. *J Biol Chem* 1997;272(40):25339-44.
166. Pagliaccia C, de Bernard M, Lupetti P, Ji X, Burrone D, Cover TL, et al. The m2 form of the *Helicobacter pylori* cytotoxin has cell type-specific vacuolating activity. *Proc Natl Acad Sci U S A* 1998;95(17):10212-7.
167. Ito Y, Azuma T, Ito S, Miyaji H, Hirai M, Yamazaki Y, et al. Analysis and typing of the vacA gene from cagA-positive strains of *Helicobacter pylori* isolated in Japan. *J Clin Microbiol* 1997;35(7):1710-4.
168. Pan ZJ, Berg DE, van der Hulst RW, Su WW, Raudonikiene A, Xiao SD, et al. Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in *Helicobacter pylori* from China. *J Infect Dis* 1998;178(1):220-6.
169. Figueiredo C, Quint WG, Sanna R, Sablon E, Donahue JP, Xu Q, et al. Genetic organization and heterogeneity of the iceA locus of *Helicobacter pylori*. *Gene* 2000;246(1-2):59-68.

170. Nishiya D, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A. Evaluation of the clinical relevance of the *iceA1* gene in patients with *Helicobacter pylori* infection in Japan. *Scand J Gastroenterol* 2000;35(1):36-9.
171. Ribeiro ML, Godoy AP, Benvenuto YH, Mendonca S, Pedrazzoli J, Jr. Clinical relevance of the *cagA*, *vacA* and *iceA* genotypes of *Helicobacter pylori* in Brazilian clinical isolates. *FEMS Immunol Med Microbiol* 2003;36(3):181-5.
172. Rota CA, Pereira-Lima JC, Blaya C, Nardi NB. Consensus and variable region PCR analysis of *Helicobacter pylori* 3' region of *cagA* gene in isolates from individuals with or without peptic ulcer. *J Clin Microbiol* 2001;39(2):606-12.
173. Yamaoka Y, El-Zimaity HM, Gutierrez O, Figura N, Kim JG, Kodama T, et al. Relationship between the *cagA* 3' repeat region of *Helicobacter pylori*, gastric histology, and susceptibility to low pH. *Gastroenterology* 1999;117(2):342-9.
174. Yamaoka Y, Orito E, Mizokami M, Gutierrez O, Saitou N, Kodama T, et al. *Helicobacter pylori* in North and South America before Columbus. *FEBS Lett* 2002;517(1-3):180-4.
175. Warburton VJ, Everett S, Mapstone NP, Axon AT, Hawkey P, Dixon MF. Clinical and histological associations of *cagA* and *vacA* genotypes in *Helicobacter pylori* gastritis. *J Clin Pathol* 1998;51(1):55-61.
176. Stephens JC, Stewart JA, Folwell AM, Rathbone BJ. *Helicobacter pylori cagA* status, *vacA* genotypes and ulcer disease. *Eur J Gastroenterol Hepatol* 1998;10(5):381-4.
177. Hennig EE, Trzeciak L, Regula J, Butruk E, Ostrowski J. *VacA* genotyping directly from gastric biopsy specimens and estimation of mixed *Helicobacter pylori* infections in patients with duodenal ulcer and gastritis. *Scand J Gastroenterol* 1999;34(8):743-9.

178. Tokumaru K, Kimura K, Saifuku K, Kojima T, Satoh K, Kihira K, et al. CagA and cytotoxicity of *Helicobacter pylori* are not markers of peptic ulcer in Japanese patients. *Helicobacter* 1999;4(1):1-6.
179. Morales-Espinosa R, Castillo-Rojas G, Gonzalez-Valencia G, Ponce de Leon S, Cravioto A, Atherton JC, et al. Colonization of Mexican patients by multiple *Helicobacter pylori* strains with different *vacA* and *cagA* genotypes. *J Clin Microbiol* 1999;37(9):3001-4.
180. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in *Helicobacter pylori* broth culture supernatants with vacuolizing cytotoxin activity. *Infect Immun* 1990;58(3):603-10.
181. Strobel S, Bereswill S, Balig P, Allgaier P, Sonntag HG, Kist M. Identification and analysis of a new *vacA* genotype variant of *Helicobacter pylori* in different patient groups in Germany. *J Clin Microbiol* 1998;36(5):1285-9.
182. Van Doorn LJ, Figueiredo C, Megraud F, Pena S, Midolo P, Queiroz DM, et al. Geographic distribution of *vacA* allelic types of *Helicobacter pylori*. *Gastroenterology* 1999;116(4):823-30.
183. Han SR, Schreiber HJ, Bhakdi S, Loos M, Maeurer MJ. *vacA* genotypes and genetic diversity in clinical isolates of *Helicobacter pylori*. *Clin Diagn Lab Immunol* 1998;5(2):139-45.
184. Mukhopadhyay AK, Kersulyte D, Jeong JY, Datta S, Ito Y, Chowdhury A, et al. Distinctiveness of genotypes of *Helicobacter pylori* in Calcutta, India. *J Bacteriol* 2000;182(11):3219-27.

185. Gonzalez-Valencia G, Atherton JC, Munoz O, Dehesa M, la Garza AM, Torres J. *Helicobacter pylori vacA* and *cagA* genotypes in Mexican adults and children. *J Infect Dis* 2000;182(5):1450-4.
186. van Doorn LJ, Figueiredo C, Rossau R, Jannes G, van Asbroek M, Sousa JC, et al. Typing of *Helicobacter pylori vacA* gene and detection of *cagA* gene by PCR and reverse hybridization. *J Clin Microbiol* 1998;36(5):1271-6.
187. Celik J, Su B, Tiren U, Finkel Y, Thoresson AC, Engstrand L, et al. Virulence and colonization-associated properties of *Helicobacter pylori* isolated from children and adolescents. *J Infect Dis* 1998;177(1):247-52.
188. Salaun L, Audibert C, Le Lay G, Buruoa C, Fauchere JL, Picard B. Panmictic structure of *Helicobacter pylori* demonstrated by the comparative study of six genetic markers. *FEMS Microbiol Lett* 1998;161(2):231-9.
189. Wang HJ, Kuo CH, Yeh AA, Chang PC, Wang WC. Vacuolating toxin production in clinical isolates of *Helicobacter pylori* with different *vacA* genotypes. *J Infect Dis* 1998;178(1):207-12.
190. Evans DG, Queiroz DM, Mendes EN, Evans DJ, Jr. *Helicobacter pylori cagA* status and s and m alleles of *vacA* in isolates from individuals with a variety of *H. pylori*-associated gastric diseases. *J Clin Microbiol* 1998;36(11):3435-7.
191. Ashour AA, Magalhaes PP, Mendes EN, Collares GB, de Gusmao VR, Queiroz DM, et al. Distribution of *vacA* genotypes in *Helicobacter pylori* strains isolated from Brazilian adult patients with gastritis, duodenal ulcer or gastric carcinoma. *FEMS Immunol Med Microbiol* 2002;33(3):173-8.

192. Faundez G, Troncoso M, Figueroa G. *cagA* and *vacA* in strains of *Helicobacter pylori* from ulcer and non-ulcerative dyspepsia patients. *BMC Gastroenterol* 2002;2(1):20.
193. Saribasak H, Salih BA, Yamaoka Y, Sander E. Analysis of *Helicobacter pylori* genotypes and correlation with clinical outcome in Turkey. *J Clin Microbiol* 2004;42(4):1648-51.
194. Hou P, Tu ZX, Xu GM, Gong YF, Ji XH, Li ZS. *Helicobacter pylori vacA* genotypes and *cagA* status and their relationship to associated diseases. *World J Gastroenterol* 2000;6(4):605-607.
195. Takata T, Fujimoto S, Anzai K, Shirotani T, Okada M, Sawae Y, et al. Analysis of the expression of *CagA* and *VacA* and the vacuolating activity in 167 isolates from patients with either peptic ulcers or non-ulcer dyspepsia. *Am J Gastroenterol* 1998;93(1):30-4.
196. Arents NL, van Zwet AA, Thijs JC, Kooistra-Smid AM, van Slochteren KR, Degener JE, et al. The importance of *vacA*, *cagA*, and *iceA* genotypes of *Helicobacter pylori* infection in peptic ulcer disease and gastroesophageal reflux disease. *Am J Gastroenterol* 2001;96(9):2603-8.
197. Miehle S, Yu J, Schuppler M, Frings C, Kirsch C, Negrusz N, et al. *Helicobacter pylori vacA*, *iceA*, and *cagA* status and pattern of gastritis in patients with malignant and benign gastroduodenal disease. *Am J Gastroenterol* 2001;96(4):1008-13.
198. Peek RM, Jr., van Doorn LJ, Donahue JP, Tham KT, Figueiredo C, Blaser MJ, et al. Quantitative detection of *Helicobacter pylori* gene expression in vivo and relationship to gastric pathology. *Infect Immun* 2000;68(10):5488-95.

199. Ashour AA, Collares GB, Mendes EN, de Gusmao VR, Queiroz DM, Magalhaes PP, et al. *iceA* genotypes of *Helicobacter pylori* strains isolated from Brazilian children and adults. *J Clin Microbiol* 2001;39(5):1746-50.
200. Pounder RE, Ng D. The prevalence of *Helicobacter pylori* infection in different countries. *Aliment Pharmacol Ther* 1995;9 Suppl 2:33-9.
201. Genta RM, Gurer IE, Graham DY. Geographical pathology of *Helicobacter pylori* infection: is there more than one gastritis? *Ann Med* 1995;27(5):595-9.
202. Lin CW, Wu SC, Lee SC, Cheng KS. Genetic analysis and clinical evaluation of vacuolating cytotoxin gene A and cytotoxin-associated gene A in Taiwanese *Helicobacter pylori* isolates from peptic ulcer patients. *Scand J Infect Dis* 2000;32(1):51-7.
203. Perng CL, Lin HJ, Sun IC, Tseng GY, Facq. *Helicobacter pylori* *cagA*, *iceA* and *vacA* status in Taiwanese patients with peptic ulcer and gastritis. *J Gastroenterol Hepatol* 2003;18(11):1244-9.



APPENDICES

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX I

MEDIA, SOLUTION AND IDENTIFICATION PROCEDURES

1. Columbia agar with 7 % sheep blood

Columbia agar base	39 g/L
Horse serum	70 ml/L
Sheep blood	70 ml/L
Distilled water	860 ml

The medium was sterilized by autoclaving at 121°C, 15 pounds/inch² pressure, for 15 minutes. The sterile medium was cooled to 45°C to 50°C. Add blood and horse serum after cooling base medium. Dispense 20 ml per petri dish. Cool and store at 4°C until used.

Do not add any heat labile components (Sheep blood or antibiotic solutions) to the sterilizer.

2. Columbia agar with 7 % Sheep blood and antibiotics

Columbia agar base	39 g/L
Horse serum	70 ml/L
Sheep blood	70 ml/L
Vancomycin (1 ml of stock)	10 mg/L
Trimethoprim (0.5 ml of stock)	5 mg/L
Cefsoludin (0.5 ml of stock)	5 mg/L
Amphotericin B (0.5 ml of stock)	5 mg/L
Distilled water	860 ml

The medium was sterilized by autoclaving at 121°C, 15 pounds/inch² pressure, for 15 minutes. The sterile medium was cooled to 45°C to 50°C. Add blood, horse serum and antibiotic solution after cooling base medium. Dispense 20 ml per petri dish. Cool and store at 4°C until used.

Do not add any heat labile components (Sheep blood or antibiotic solutions) to the sterilizer.

3. Antibiotic solution preparation

Vancomycin, final concentration 10 mg/L

- Prepare a stock solution, dissolve 0.028 g in 5.78 ml distilled water

Cefsoludin, final concentration 5 mg/L

- Prepare a stock solution, dissolve 0.014 g in 2.82 ml distilled water.

Trimethoprim, final concentration 5 mg/L

- Prepare a stock solution, dissolve 0.018 g in 3.7 ml distilled water.

Amphotericin, final concentration 5 mg/L

- Prepare a stock solution, dissolve 0.014 g in 2.84 ml distilled water.

4. Urease test

Solution A : for 20 ml

Urea agar base (BBL)	2.9 g
Urea	4 g
Distilled water	20 ml

Dissolve in 20 ml of distilled water. Adjust to pH 6.2 Sterilize by filtration (use a 0.22 μ M filter).

Solution B : for 80 ml

Bacto agar (Difco)	0.5 g
Distilled water	80 ml

Add the ingredient to 80 ml of distilled water ; heat with stirring until the agar is dissolved. Sterilize by autoclaving at 121°C, 15 ponds/inch² pressure, for 15 minutes. Mix solution A, 20 ml with solution B, 80 ml. Aliquot into sterile 1.5 microtube (1 ml/tube). Test the sterility of Urease medium by incubate tubes at 37°C for 24 hours. Store tubes in refrigerator at 4°C until used.

5. Brain heart infusion with 20 % glycerol

Brain heart infusion	37 g/L
Glycerol	200 ml
Distilled water	800 ml

Sterilize by autoclaving at 121°C, 15 pounds/inch² pressure, for 15 minutes. Aliquot into sterile screw cap tubes (1 ml/tube). Store tubes in refrigerator at 4°C until used.

6. Sterile saline solution

Sodium Chloride	8.5 g/L
Distilled water	1 L

Sterilize by autoclaving at 121°C, 15 pounds/inch² pressure, for minutes. Store at room temperature.



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX II**REAGENTS, MATERIALS AND INSTRUMENTS****A. REAGENTS**

Absolute ethanol	(Merck, Germany)
Agarose	(Biorad, U.S.A.)
Brain heart infusion agar	(Oxoid, U.S.A.)
EDTA	(Amresco, U.S.A.)
Ethidium bromide	(Amresco, U.S.A.)
Glacial acetic acid	(Merck, Germany)
Horse serum	(GibcoBRL, U.S.A.)
Miniral oil	(Sigma, U.S.A.)
Columbia agar base	(Oxoid, U.S.A.)
Urea agar base	(BBL, U.S.A.)
Bacto agar	(Difco, U.S.A.)
NaCl	(Merck, Germany)
NaHCO ₃	(Merck, Germany)
Na ₂ HPO ₄ *2H ₂ O	(Sigma, U.S.A.)
Tris	(Amresco, U.S.A.)

B. MATERIALS

Anaerobic jar	(BBL, U.S.A.)
Gas pack	(Oxoid, U.S.A.)

C. INSTRUMENTS

Water bath	(Mettler, U.S.A.)
Perkin Elmer GeneAmp PCR system 9600	(Perkin Elmer, U.S.A.)
Camera Gel Doc™ MZL	(BIO-RAD, U.S.A.)
Incubator	(BIO-RAD, U.S.A.)
Microcentrifuge	(Eppendorf, U.S.A.)
Spectrophotometer	(BIO-RAD, U.S.A.)



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX III**REAGENTS AND PREPARATION****1. 5x Tris-borate buffer (TBE)**

Tris base	54 g/L
Boric acid	27.5 g/L
0.5 M EDTA (pH 8.0)	20 ml

Adjust volume to 1 liter with distilled water. The solution was mixed and sterilized by autoclaving at 121°C for 15 min.

2. 0.5 M EDTA (pH 8.0)

Disodium ethylene diamine tetraacetate 2H ₂ O	186.1 g/L
Distilled water	1 L

Adjust pH to 8.0 and volume to 1 liter. Store at room temperature for no longer than 1 year.

3. 10x TE buffer

Tris	12.11 g/L
0.5 M EDTA	20 ml

Adjust to pH 8.0 by adding conc. HCl, Adjust volume to 1,000 ml and sterilized by autoclaving at 121°C for 15 min.

จุฬาลงกรณ์มหาวิทยาลัย

4. 2 % Agarose gel

Agarose	0.4 g
1x TBE	20 ml

Dissolve by heating in microwave oven and occasional mix unit no granules of agarose are visible.

5. 5x Loading buffer 100 ml

Tris HCl	0.6 g
EDTA	1.68 g
SDS	0.5 g
Bromphenol Blue	0.1 g
Sucrose	40 g

Adjust volume to 100 ml with distilled water. Mix the solution, aliquot into 1.5 microtube and store at 4°C.



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

BIOGRAPHY

Miss Janjira Thongtem was born on September 25, 1979 in Nakornsithamarat, Thailand. She graduated with the Bachelor degree of science in Microbiology from Prince of Songkla University in 2002 and then attended to particulate in Medical Microbiology program, Graduate School, Chulalongkorn University for her Master's Degree



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย